The effect of doxorubicin treatment on variant rs22297749/S427L)-dependent transcriptome changes in patient-derived human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).

We investigate transcriptome changes of variant S427L and control hiPSC–CMs in response to 1 µM doxorubicin for 24 h, using an unbiased approach Overall design: Day 30 hiPSC–CMs from 6 patients (3 Control and 3 S427L) were treated with 1 mM doxorubicin or vehicle for 24 h. We have previously determined that this is a physiologically relevant dose (Burridge et al., 2016)